Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden

5 Jan 2024

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Disease Management and Epidemiology
Share to Bacillus and Francisella bacterial research
Share to Viral gastroenteritis research and epidemiology

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38190833
DOI: 10.1016/s1473-3099(23)00779-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in SwedenPMID 38190833Read ↗

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancerSemantic proximity Read ↗

Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responsesSemantic proximity Read ↗

Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trialSemantic proximity Read ↗

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasmsSemantic proximity Read ↗

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVacSemantic proximity Read ↗

Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantationSemantic proximity Read ↗

Determination of significant immunological timescales from mRNA-LNP-based vaccines in humansSemantic proximity Read ↗

Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipientsSemantic proximity Read ↗

Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent boosterSemantic proximity Read ↗

Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO/MPP mRNA Technology Transfer Programme meeting reportSemantic proximity Read ↗

Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine.Semantic proximity Read ↗

Humoral and T-cell responses following MVA-BN booster vaccination against mpox virus clades Ib and IIbSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.